These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Octreotide as primary therapy for acromegaly. Newman CB; Melmed S; George A; Torigian D; Duhaney M; Snyder P; Young W; Klibanski A; Molitch ME; Gagel R; Sheeler L; Cook D; Malarkey W; Jackson I; Vance ML; Barkan A; Frohman L; Kleinberg DL J Clin Endocrinol Metab; 1998 Sep; 83(9):3034-40. PubMed ID: 9745397 [TBL] [Abstract][Full Text] [Related]
3. Outcome of gamma knife radiosurgery in 82 patients with acromegaly: correlation with initial hypersecretion. Castinetti F; Taieb D; Kuhn JM; Chanson P; Tamura M; Jaquet P; Conte-Devolx B; Régis J; Dufour H; Brue T J Clin Endocrinol Metab; 2005 Aug; 90(8):4483-8. PubMed ID: 15899958 [TBL] [Abstract][Full Text] [Related]
4. Long-term results of stereotactic radiosurgery in secretory pituitary adenomas. Castinetti F; Nagai M; Morange I; Dufour H; Caron P; Chanson P; Cortet-Rudelli C; Kuhn JM; Conte-Devolx B; Regis J; Brue T J Clin Endocrinol Metab; 2009 Sep; 94(9):3400-7. PubMed ID: 19509108 [TBL] [Abstract][Full Text] [Related]
5. Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size. Bevan JS; Atkin SL; Atkinson AB; Bouloux PM; Hanna F; Harris PE; James RA; McConnell M; Roberts GA; Scanlon MF; Stewart PM; Teasdale E; Turner HE; Wass JA; Wardlaw JM J Clin Endocrinol Metab; 2002 Oct; 87(10):4554-63. PubMed ID: 12364434 [TBL] [Abstract][Full Text] [Related]
6. Radiosurgery for growth hormone-producing pituitary adenomas. Zhang N; Pan L; Wang EM; Dai JZ; Wang BJ; Cai PW J Neurosurg; 2000 Dec; 93 Suppl 3():6-9. PubMed ID: 11143264 [TBL] [Abstract][Full Text] [Related]
7. Stereotactic conformal radiotherapy in patients with growth hormone-secreting pituitary adenoma. Milker-Zabel S; Zabel A; Huber P; Schlegel W; Wannenmacher M; Debus J Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1088-96. PubMed ID: 15234043 [TBL] [Abstract][Full Text] [Related]
8. Gamma knife radiosurgery for acromegaly--long-term experience. Jezková J; Marek J; Hána V; Krsek M; Weiss V; Vladyka V; Lisák R; Vymazal J; Pecen L Clin Endocrinol (Oxf); 2006 May; 64(5):588-95. PubMed ID: 16649981 [TBL] [Abstract][Full Text] [Related]
9. Gammaknife radiosurgery in patients with acromegaly. Erdur FM; Kilic T; Peker S; Celik O; Kadioglu P J Clin Neurosci; 2011 Dec; 18(12):1616-20. PubMed ID: 22001240 [TBL] [Abstract][Full Text] [Related]
10. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. Cozzi R; Montini M; Attanasio R; Albizzi M; Lasio G; Lodrini S; Doneda P; Cortesi L; Pagani G J Clin Endocrinol Metab; 2006 Apr; 91(4):1397-403. PubMed ID: 16449332 [TBL] [Abstract][Full Text] [Related]
12. Long-term follow-up of patients with surgical intractable acromegaly after linear accelerator radiosurgery. Yan JL; Chang CN; Chuang CC; Hsu PW; Lin JD; Wei KC; Lee ST; Tseng JK; Pai PC; Chen YL J Formos Med Assoc; 2013 Jul; 112(7):416-20. PubMed ID: 23927981 [TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of higher dose stereotactic radiosurgery for functional pituitary adenomas: a preliminary report. Grant RA; Whicker M; Lleva R; Knisely JP; Inzucchi SE; Chiang VL World Neurosurg; 2014; 82(1-2):195-201. PubMed ID: 23385448 [TBL] [Abstract][Full Text] [Related]
14. Four years' experiences in the treatment of pituitary adenomas with gamma knife radiosurgery. Lim YL; Leem W; Kim TS; Rhee BA; Kim GK Stereotact Funct Neurosurg; 1998 Oct; 70 Suppl 1():95-109. PubMed ID: 9782241 [TBL] [Abstract][Full Text] [Related]
15. Gamma-knife surgery is effective in normalising plasma insulin-like growth factor I in patients with acromegaly. Gutt B; Wowra B; Alexandrov R; Uhl E; Schaaf L; Stalla GK; Schopohl J Exp Clin Endocrinol Diabetes; 2005 Apr; 113(4):219-24. PubMed ID: 15891958 [TBL] [Abstract][Full Text] [Related]
16. Lanreotide 60 mg, a new long-acting formulation: effectiveness in the chronic treatment of acromegaly. Attanasio R; Baldelli R; Pivonello R; Grottoli S; Bocca L; Gasco V; Giusti M; Tamburrano G; Colao A; Cozzi R J Clin Endocrinol Metab; 2003 Nov; 88(11):5258-65. PubMed ID: 14602759 [TBL] [Abstract][Full Text] [Related]
17. Transsphenoidal surgery for acromegaly in wales: results based on stringent criteria of remission. De P; Rees DA; Davies N; John R; Neal J; Mills RG; Vafidis J; Davies JS; Scanlon MF J Clin Endocrinol Metab; 2003 Aug; 88(8):3567-72. PubMed ID: 12915637 [TBL] [Abstract][Full Text] [Related]
18. Ten-year follow-up results of transsphenoidal microsurgery in acromegaly. Biermasz NR; van Dulken H; Roelfsema F J Clin Endocrinol Metab; 2000 Dec; 85(12):4596-602. PubMed ID: 11134114 [TBL] [Abstract][Full Text] [Related]
19. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue? Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503 [TBL] [Abstract][Full Text] [Related]
20. Radiosurgery of growth hormone-producing pituitary adenomas: factors associated with biochemical remission. Pollock BE; Jacob JT; Brown PD; Nippoldt TB J Neurosurg; 2007 May; 106(5):833-8. PubMed ID: 17542527 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]